Polymorphisms in ADAR1 gene affect response to interferon alpha based therapy for chronic hepatitis B in Han Chinese.

[1]  M. Rizzetto,et al.  A Practical Guide to the Use of Interferons in the Management of Hepatitis Virus Infections , 2012, Drugs.

[2]  C. Samuel,et al.  Adenosine deaminases acting on RNA (ADARs) are both antiviral and proviral. , 2011, Virology.

[3]  N. Niu,et al.  Human leukocyte antigen class I and class II genes polymorphisms might be associated with interferon α therapy efficiency of chronic hepatitis B. , 2011, Antiviral research.

[4]  A. Koike,et al.  Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C , 2009, Nature Genetics.

[5]  Thomas Berg,et al.  IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy , 2009, Nature Genetics.

[6]  Jacques Fellay,et al.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance , 2009, Nature.

[7]  Jing-yun Li,et al.  A pharmacogenetic study of polymorphisms in interferon pathway genes and response to interferon-alpha treatment in chronic hepatitis B patients. , 2009, Antiviral research.

[8]  Arcadi Navarro,et al.  Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. , 2009, Archives of neurology.

[9]  William M. Lee,et al.  Variants in interferon‐alpha pathway genes and response to pegylated interferon‐Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long‐term treatment against cirrhosis trial , 2009, Hepatology.

[10]  Yusuke Nakamura,et al.  A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C. , 2009, Gastroenterology.

[11]  N. Terrault.  Benefits and risks of combination therapy for hepatitis B , 2009, Hepatology.

[12]  R. Perrillo.  Benefits and risks of interferon therapy for hepatitis B , 2009, Hepatology.

[13]  Yong-yong Shi,et al.  SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci , 2023, Cell Research.

[14]  Nicole Soranzo,et al.  A single-nucleotide polymorphism tagging set for human drug metabolism and transport , 2005, Nature Genetics.

[15]  D. Ganem,et al.  Hepatitis B virus infection--natural history and clinical consequences. , 2004, The New England journal of medicine.

[16]  S. Hadziyannis,et al.  Current management of chronic hepatitis B , 2004, Alimentary pharmacology & therapeutics.

[17]  S. Hadziyannis,et al.  Review article: current management of chronic hepatitis B. , 2004, Alimentary pharmacology & therapeutics.

[18]  D. Kalvakolanu,et al.  Alternate interferon signaling pathways. , 2003, Pharmacology & therapeutics.

[19]  Ding‐Shinn Chen,et al.  Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot study , 2002, Hepatology.

[20]  C. Samuel,et al.  Antiviral Actions of Interferons , 2001, Clinical Microbiology Reviews.

[21]  C. Samuel,et al.  Human RNA-specific adenosine deaminase ADAR1 transcripts possess alternative exon 1 structures that initiate from different promoters, one constitutively active and the other interferon inducible. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[22]  K. Nishikura,et al.  Genomic organization and chromosomal location of the human dsRNA adenosine deaminase gene: the enzyme for glutamate-activated ion channel RNA editing. , 1995, Journal of molecular biology.

[23]  C. Samuel,et al.  The interferon-inducible, double-stranded RNA-specific adenosine deaminase gene (DSRAD) maps to human chromosome 1q21.1-21.2. , 1995, Genomics.

[24]  C. Samuel,et al.  forms of the deaminase . deaminase from human cells : evidence for two double-stranded-RNA-specific adenosine Expression and regulation by interferon of a , 1995 .

[25]  P. Marcellin,et al.  Treatment of chronic viral hepatitis. , 1994, Bailliere's clinical gastroenterology.